JBC Ideal method for primary cell transfection

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M511024200 on December 30, 2005

J. Biol. Chem., Vol. 281, Issue 10, 6760-6767, March 10, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/10/6760    most recent
M511024200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, J. K.
Right arrow Articles by Levin, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, J. K.
Right arrow Articles by Levin, E. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Estrogen Prevents Cardiomyocyte Apoptosis through Inhibition of Reactive Oxygen Species and Differential Regulation of p38 Kinase Isoforms*

Jin Kyung Kim{ddagger}, Ali Pedram§, Mahnaz Razandi§, and Ellis R. Levin§1

From the Divisions of {ddagger}Cardiology and Endocrinology, University of California, Irvine, California 92717 and the §Division of Endocrinology, Long Beach Veterans Affairs Medical Center, Long Beach, California 90822

Received for publication, October 11, 2005 , and in revised form, December 5, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
From human and animal studies, estrogen is known to protect the myocardium from an ischemic insult. However, there is limited knowledge regarding mechanisms by which estrogen directly protects cardiomyocytes. In this report, we employed an in vitro model, in which cultured rat cardiomyocytes underwent prolonged hypoxia followed by reoxygenation (H/R), to study the cardioprotective mechanism of estrogen. 17-beta-estradiol (E2) acting via estrogen receptors inhibited H/R-induced apoptosis of cardiomyocytes. Mitochondrial reactive oxygen species (ROS) generated from H/R activated p38{alpha} MAPK, and inhibition of p38{alpha} with SB203580 significantly prevented H/R-induced cell death. E2 suppressed ROS formation and p38{alpha} activation by H/R and concomitantly augmented the activity of p38beta. Unlike p38{alpha}, p38beta was little affected by H/R. Dominant negative p38beta protein expression decreased E2-mediated cardiomyocyte survival and ROS suppression during H/R stress. The prosurvival signaling molecule, phosphoinositol-3 kinase (PI3K), has previously been linked to cell survival following ischemia-reperfusion injury. Here, E2-activated PI3K was found to inhibit ROS generated from H/R injury, leading to inhibition of downstream p38{alpha}. We further linked these signaling pathways in that p38beta was activated by E2 stimulation of PI3K. Thus, E2 differentially modulated two major isoforms of p38, leading to cardiomyocyte survival. This was achieved by signaling through PI3K, integrating cell survival mediators.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Ischemic heart disease with subsequent myocardial infarction and congestive heart failure is the leading cause of mortality in this country (1). The incidence of ischemic heart disease is significantly lower in women than in men until menopause, after which the cardiovascular risk of women accelerates to equal that of men (2, 3). This observation suggests a possibility that female sex hormones, such as estrogen, may have a favorable cardiovascular role. There is evidence from epidemiological, animal, and in vitro studies that estrogen may be cardioprotective (4). For example, postmenopausal women on hormone replacement therapy have a lower mortality than non-users of hormone replacement therapy (5), and meta-analysis shows that women have a better prognosis after myocardial infarction than men after age and other factors are adjusted (6). In animal models, 17beta-estradiol (E2)2 reduces myocardial necrosis in rabbits (7) and prevents global myocardial ischemia/reperfusion (I/R) injury in rats (8). Given such protection of the heart from an ischemic insult, it is possible that estrogen directly acts at the level of individual cardiomyocytes. How estrogen protects the myocardium is not well understood currently.

Considering the reported anti-apoptotic effect of estrogen on diverse cell types (9-13), cardioprotection by estrogen may be due to prevention of cardiomyocyte apoptosis, after ischemic or oxidative stress. Loss of cardiomyocytes by apoptotic death has been associated with myocardial infarction (14), I/R injury (15, 16), or end-stage heart failure (17). Supporting evidence to date suggests that estrogen plays an anti-apoptotic role in the heart. Estrogen replacement in ovariectomized female mice is associated with a smaller infarct size and reduced apoptosis in the peri-infarct zone of the left ventricle after coronary artery ligation and release (18). When cultured neonatal cardiomyocytes were induced to undergo programmed cell death by drugs such as daunorubicin, the presence of E2 reduced myocyte apoptosis by activating pro-survival PI3K/Akt signaling (18).

With numerous modulators involved in cell fate, different stressors are likely to activate different initial signaling pathways leading to cardiomyocytes apoptosis. One model of cardiac apoptosis is that of I/R injury, associated with both the ischemic and the reperfused heart (14, 19-21). Perhaps this is related to the bursts of reactive oxygen species (ROS) that are generated during both stages (15). ROS is thought to be a potent stimulator of apoptosis as part of I/R injury (22).

It is, therefore, plausible that estrogen may attenuate the generation or actions of ROS resulting from oxidative stress following I/R. Additional mechanisms described in other cell models may be involved in I/R-induced apoptosis (11, 13). This includes p38 mitogen-activated protein kinase (p38 MAPK), generally stimulated by heterogeneous forms of cellular stress. The importance of p38 MAPK in the heart was well displayed in vivo when rats treated with a specific inhibitor of p38 displayed less remodeling and ventricular dysfunction after myocardial infarction (23). In addition, transgenic mice expressing a dominant negative p38 mutant were partially protected from I/R injury (24). There are four isoforms of p38: {alpha}, beta, {delta}, and {gamma}. Both p38{alpha} and p38beta are found in the human heart, although the former is more abundant in ischemic or failing hearts (25-27).

In this study, we describe several molecular mechanisms by which estrogen protects myocytes from I/R-related cell death. Using cultured neonatal rat cardiomyocytes and an established in vitro system of hypoxia followed by reoxygenation (H/R) to simulate I/R, we dissected the relationship among E2-activated estrogen receptor (ER), mitochondrial ROS generation, p38{alpha} and p38beta MAPK isoforms, and PI3K in the net outcome of myocyte survival. We report the novel findings that E2 differentially modulates p38{alpha} and beta isoforms in the cardiomyocyte, preventing apoptosis during hypoxic/oxidative stress.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Harvest and Culture of Neonatal Rat Cardiomyocytes—All studies were approved by the Research and Development and Animal Use Committees of the Long Beach Veterans Affairs Medical Center. Myocytes were isolated from the hearts of 1-3-day-old rats (Sprague-Dawley) using a neonatal cardiomyocyte isolation system kit (Worthington) as reported previously (28). Synchronous spontaneously contracting cells in a single layer were plated at 1.5 x 106 cells/ml density after 1 h of differential plating to remove non-myocytes. Greater than 99% of the population was determined to be cardiomyocytes by immunostaining with cardiac myosin heavy chain monoclonal antibody (AbCam). The cells were grown in L-15 Leibovitz culture medium supplemented with 10% fetal bovine serum in a standard tissue culture incubator.

Simulated Ischemia-Reperfusion Model—Neonatal rat cardiomyocytes were synchronized in serum-free L-15 Leibovitz culture medium overnight and treated with 10 nM E2 ± reagents of interest or control vehicle. The cells were placed into an anaerobic chamber (GasPack system, BD Biosciences) for 18 h, which was purged with 95% N2, 5% CO2 and sealed with an oxygen-consuming palladium catalyst. This created a hypoxic condition of 25-35 mm Hg PO2. Following hypoxia, the chamber was opened to air, and cells were placed in a standard incubator for reoxygenation for 1 h before further assays.

Cell Viability—After simulated ischemia-reperfusion, cells were stained with trypan blue dye and counted on a hemocytometer. Five hundred cells were counted per field per experimental condition. The study was repeated three times, and data were combined and analyzed for statistical significance.

Apoptosis Assays—Early stages of apoptosis were assessed by annexin V-FITC fluorescence microscopy kit (Pharmingen) according to the manufacturer's protocol. Briefly, cells were washed with annexin V binding buffer, incubated with annexin V-FITC for 15 min at room temperature, and then counterstained with Hoechst 33342 for nuclei, washed, and visualized by FITC analysis.

Late stages of apoptosis were also assessed, using the DeadEndTMFluorometric TUNEL system (Promega) according to the manufacturer's instruction. Briefly, cells in culture were washed after H/R, fixed with 4% formaldehyde in phosphate-buffered saline, permeabilized with Triton® X-100, labeled with flurorescein-12-dUTP, and stained with Hoechst 33342 for nuclei, and green fluorescence of apoptotic cells was analyzed by fluorescence microscopy.

Necrotic cells were detected by differential propidium iodide (PI) and Hoechst 33342 staining. Intact membranes of healthy cells exclude PI, whereas necrotic cells are stained brightly with PI after a short incubation. Briefly, cardiomyocytes grown on glass-bottomed, 35-mm culture dishes underwent overnight hypoxia followed by reoxygenation and then were washed, incubated with 1.5 µg/ml Hoechst 33342 in phosphate-buffered saline for 15 min at room temperature, washed again, incubated with 4 µg/ml PI in phosphate-buffered saline for 30 min at room temperature, and then visualized under the fluorescence microscope. From each condition, 500 cells were counted. Experiments were repeated three times and statistically analyzed as below.

ROS Detection—At the end of hypoxia-reoxygenation, cells were assayed for intracellular ROS by using Image-iTTMLIVE green reactive oxygen species detection kit (Molecular Probes), counterstained with Hoechst 33342 for nuclei, and imaged under a microscope, using fluorescein filter sets.

p38 Immunoprecipitation and Kinase Studies—Cardiomyocytes were synchronized in serum-free medium and then incubated with or without E2 (10 nM), with or without 1 µM ICI182780, and/or with or without 1 µM SB203580. Hypoxia-reoxygenation was then applied as above. Cells were then lysed, and the lysate was immunoprecipitated for p38{alpha} or beta kinase using polyclonal anti-p38{alpha} or anti-p38beta antibody (Santa Cruz Biotechnology) conjugated to Sepharose beads, respectively. Cell lysate was then used for in vitro kinase assays with ATF2 as substrate, as described previously (11). The phosphorylated substrate was separated on 10% SDS-PAGE gel and detected by autoradiography, and the bands were quantitated by laser densitometry. Western blotting for total p38{alpha} or p38beta was performed to demonstrate equal amounts of immunoprecipitated kinase proteins for each condition.

Western Blotting—After H/R was applied, cardiomyocytes were lysed and loaded onto 10% SDS-PAGE gel in the same manner as above. Proteins were transferred to nitrocellulose membrane, which was blocked with 3% nonfat milk and 2% bovine serum albumin in 0.05% Tween-Tris-buffered saline buffer. After binding with primary antibody against p38{alpha}, p38beta, phosphorylated Akt, or total Akt protein (Santa Cruz Biotechnology), the membrane was washed, and then secondary antibody was applied. The membrane was then incubated with chemiluminescence reagents using a commercially available kit (ECL Plus Western blotting detection system, Amersham Biosciences) and exposed to film.

Adenoviral Infection—Adenoviruses expressing dominant negative p38beta MAPK were generously provided by Dr. Jiahuai Han (Scripps Research Institute, La Jolla, CA) (29). Viruses were amplified and titrated in 293 cells. The suppression of the p38 activity in cardiomyocytes was confirmed by immunoprecipitation of the kinase from the infected cells and kinase activity assay as described above. Viral stocks at a multiplicity of infection of 25-50 particles/cell were used to infect cardiomyocytes overnight. The cells were fed fresh medium the following day and further incubated for 24 h until ready for experiments. Experiments were performed 36-48 h after infection.

Statistical Analysis—All experiments were repeated at least three times. Data were combined and analyzed by Student's t test using GB-Stat software for statistical significance at p value < 0.05.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
ER Protects Cardiomyocyte from Apoptosis by Suppressing p38{alpha} Following Simulated I/R—Approximately 60% of cardiomyocytes were found to be non-viable after undergoing overnight hypoxia followed by reoxygenation (Fig. 1A). Cell death was significantly reversed in the presence of 10 nM E2. ICI182780, a specific inhibitor of ER, demonstrated involvement of ER in the cell survival actions of the steroid hormone. A large portion of cell death was due to apoptosis, as evidenced by positive annexin V staining (measuring the early stages of apoptosis), significantly prevented by E2 (Fig. 1B, left panel). The anti-apoptotic action of E2 was prevented by ICI182780. A second method, the deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL) assay (assessing late stages of DNA fragmentation), also illustrated E2 prevention of cardiomyocyte apoptosis (Fig. 1B, right). Death due to necrosis was less than 5% of the total cell population in our H/R system (data not shown), as determined by strong uptake of PI in necrotic cells, in contrast to PI-negative cells (30).

We then sought to delineate molecular mechanisms by which E2 reduced apoptosis. Prominent signaling molecules activated under a variety of cellular stresses include the p38 MAPK family. Here, blocking p38 kinase activity with a specific inhibitor, SB203580, resulted in a reduced number of apoptotic myocytes (Fig. 2). This occurred in a similar magnitude to survival induced by E2, and the effects of SB203580 + E2 were not different from either alone. Although SB203580 is a soluble inhibitor of both p38{alpha} and p38beta (31, 32), our finding is consistent with a previously published report that showed, by using a SB203580-resistant p38{alpha} mutant, that the anti-ischemic effect of SB203580 was through inhibition of p38{alpha} (33). We examined whether the improved cell survival due to E2 correlated with suppression of p38{alpha} by the hormone (Fig. 3). Following H/R, p38{alpha} kinase activity increased. E2 efficiently blocked the activity of this pro-apoptotic kinase, and antagonizing ER with ICI182780 restored the activity of p38{alpha}. Therefore, inhibition of p38{alpha} by E2/ER contributes to cardiomyocyte survival.


Figure 1
View larger version (18K):
[in this window]
[in a new window]
  		FIGURE 1.
Effect of E2 on survival of cardiomyocytes following simulated ischemia-reperfusion. A, H/R resulted in non-viable cells taking up trypan blue dye. 10 nM E2 reversed this effect. The E2 effect was antagonized by an ER inhibitor ICI182780 (ICI) at 100 nM. The presence of E2 in control normoxic condition did not cause significant change in cell viability. B, apoptosis of cardiomyocytes was identified by annexin V FITC (left) and TUNEL staining (right). The concentrations of E2, ICI182780, and H/R condition were the same as in panel A. Lanes not labeled with H/R represented experiments performed in normoxia. *, p < 0.01 versus normoxia. +, p < 0.01 versus H/R. ++, p < 0.05 versus H/R + E2.

 
Estrogen Blocks the Generation of ROS Upstream of p38{alpha} in Apoptotic Signaling—We then examined at which steps of the apoptotic process the E2-p38 interaction interceded. Apoptosis in general can be either death receptor-mediated (extrinsic pathway) or via cytochrome c release from mitochondria (intrinsic pathway). Human cardiomyocytes have the highest density of mitochondria of all mammalian cells (34). Mitochondria play a key role in apoptosis, releasing apoptotic factors into the cytosol. Ischemia/reperfusion generates ROS, potent inducers of cardiac apoptosis (22), and a majority of ROS originates from mitochondria during oxidative stress. We postulated that E2 would affect ROS-driven apoptosis and tested whether attenuation of apoptosis by E2 was linked to reduction of ROS. After myocytes underwent H/R, intracellular ROS was detected using 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate-based assay (Fig. 4A). Considerably more ROS was observed following H/R, when compared with the normoxic condition, as expected. Most of ROS were generated from mitochondria, as rotenone suppressed ROS following H/R. Rotenone inhibits the mitochondrial electron transport complex I and is known to inhibit mitochondrial ROS generation in cardiac cells (35, 36). We also used another specific inhibitor of mitochondrial ROS, Mito-Q (37), to confirm that ROS detected in our system were from mitochondria (data not shown).

In the presence of E2, the ROS level diminished significantly. In contrast, blocking p38 with SB203580 did not alter the amount of ROS generated significantly. We derived from this result that 1) E2 efficiently blocks ROS generation during H/R and 2) ROS may act upstream of p38{alpha}.


Figure 2
View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 2.
Role of p38 in apoptosis of cardiomyocytes following H/R. Apoptotic cells detected by positive annexin V staining were presented as a percentage of total number of cells counted. Concentrations of E2 and SB203580 (SB) were 10 nM and 1 µM, respectively. Lanes not labeled with H/R represented experiments performed in normoxia. *, p < 0.01 versus normoxia. +, p < 0.01 versus H/R.

 


Figure 3
View larger version (36K):
[in this window]
[in a new window]
  		FIGURE 3.
E2 effect on p38{alpha} activity in cardiomyocytes. Kinase activity was measured by detecting the phosphorylation of a substrate, ATF2, by p38{alpha} immunoprecipitated from the cells. Concentrations of E2, ICI182780 (ICI), and SB203580 (SB) were 10 nM, 100 nM, and 1 µM, respectively. Western blotting of immunoprecipitated total p38{alpha} demonstrated equal loading of kinase proteins from each condition. Lanes not labeled with H/R represented experiments performed in normoxia. *, p < 0.05 versus normoxia. +, p < 0.05 versus H/R.

 
To confirm that ROS is upstream of p38{alpha}, we examined the kinase activity in the presence of ROS inhibitors, rotenone and N-acetyl-cysteine (NAC). The p38{alpha} activity decreased drastically in the presence of rotenone or NAC (Fig. 4B), consistent with a previous report demonstrating that mitochondrial ROS can initiate p38 MAPK phosphorylation (38). Blockade of ROS generation and subsequent inhibition of p38{alpha}, by rotenone or NAC, led to better survival of cardiomyocytes, as shown in Fig. 4C. Also implied from the marked reversal of apoptosis by rotenone is that a significant stimulus for cell death during H/R arises from mitochondrial ROS production. Taken together, an important mechanism for the survival of cardiomyocytes conferred by E2/ER during H/R stems from inhibition of both ROS generation and subsequent p38{alpha} kinase activation.

Estrogen Up-regulation of p38beta Is Essential in Cardiomyocyte Survival—Among the four known p38 isoforms ({alpha}, beta, {delta}, and {gamma}), mainly p38{alpha} and p38beta are expressed in the heart (26). The two kinases also have opposing effects on apoptosis. In contrast to the pro-apoptotic property of p38{alpha}, p38beta can enhance cell survival (11, 29). We hypothesized that anti-apoptotic actions of E2/ER could involve inverse regulation of the two p38 subtypes during the H/R-related injury. E2 alone was found to up-regulate p38beta significantly during normoxia or H/R (Fig. 5A). Additionally, p38beta kinase activity was not significantly altered by hypoxic/oxidative stress in the absence of E2.

To confirm that p38beta is essential for the E2-mediated rescue of cardiomyocytes, we suppressed endogenous p38beta function and determined the extent of the cell death. This was accomplished by expressing a dominant negative p38beta construct (p38b DN) (Fig. 5B) containing a TGY -> AGF mutation in the activating phosphorylation site. This mutation renders the kinase inactive (29). When the p38b DN protein was expressed, E2 no longer stimulated p38beta activity. Upon application of H/R to these p38b DN-expressing cells, the anti-apoptotic effect of E2 was substantially reduced (Fig. 5C). We inferred from these results that a large part of E2 protection of cardiomyocytes under ischemic/oxidative stress was due to activation of p38beta.

As shown above, an important trigger for the myocyte to undergo H/R-induced apoptosis was the generation of ROS. Given the interaction of E2 and p38beta necessary for myocyte survival above, we postulated that E2-activated p38beta might decrease the oxidative stress. Thus, we examined ROS production in cells expressing p38b DN mutant (Fig. 5D). As before, H/R significantly increased the generation of ROS, which was strongly suppressed by E2. Expressing dominant negative p38beta kinase, however, led to a large percentage of cells producing ROS in the presence of E2. Counteraction of steroid-mediated ROS suppression by the dominant negative kinase suggests a novel mechanism for E2 and p38beta in abrogating the oxidative stress response in cardiomyocytes.

E2 Regulates Multiple Points of Signaling to Cell Survival—A previously published report suggests that E2 stimulates PI3K/Akt, reducing apoptosis in the heart during H/R (18). Furthermore, MAPK family proteins and PI3K may form an integrative signaling network important for regulation of apoptosis (39). We speculated that PI3K might interact with p38{alpha} and/or p38beta in our experimental setting. Alternatively, PI3K activity may represent a parallel pathway to cell survival.

We therefore determined whether the rescue from oxidative stress was a mechanism behind E2-PI3K protection. We performed H/R experiments in the presence and absence of a PI3K inhibitor, wortmannin, and examined intracellular ROS (Fig. 6A). In the presence of wortmannin, reduction of ROS by E2 was reversed, suggesting that E2 signaling through PI3K prevents ROS generation. Blocking PI3K with wortmannin resulted in a higher level of ROS even at normoxia. This observation raised an interesting possibility that PI3K may be involved in baseline control of ROS turnover in a cardiomyocyte. Since we showed that ROS was upstream of p38{alpha}, our results suggest an interactive signaling pathway modulated by E2.


Figure 4
View larger version (54K):
[in this window]
[in a new window]
  		FIGURE 4.
Effect of E2 on ROS production. A, intracellular ROS appeared green under fluorescent microscopy. Concentrations E2 and SB203580 (SB) used were 10 nM and 1 µM, respectively. Rotenone at a concentration of 2.5 µM was used to inhibit mitochondrial ROS. B, p38{alpha} activity following ROS inhibition. ATF2 phosphorylation by p38{alpha} kinase was performed in the presence or absence of ROS inhibitors, rotenone (Rot), and NAC. Concentrations of rotenone and NAC were 2.5 µM and 1 mM, respectively. Western blotting of immunoprecipitated total p38{alpha} showed equal loading of kinase proteins from each condition. *, p < 0.05 versus normoxia. +, p < 0.05 versus H/R. C, the effect of ROS inhibitors on apoptosis. Annexin V-positive cells were expressed as percentage of total number of cells counted. Concentrations of rotenone and NAC remained the same as in panel B. Lanes not labeled with H/R represented experiments performed in normoxia. *, p < 0.05 versus normoxia. +, p < 0.01 versus H/R.

 
To further probe the relationship between PI3K and E2 in ROS-induced apoptosis, we assessed p38{alpha} activity in the presence of the PI3K inhibitor (Fig. 6B). As expected, p38{alpha} activity was increased in H/R and blocked by E2. However, E2-mediated inhibition of p38{alpha} was significantly reversed by blocking PI3K. Wortmannin alone did not affect p38{alpha} in the presence or absence of H/R. This illustrates that PI3K plays a novel intermediary role in E2 inhibition of p38{alpha}, in the setting of cardiomyocyte stress.

Akt is an anti-apoptotic protein whose phosphorylation and activation depends on PI3K (10, 18). We detected p-Akt by Western blotting to assess the functional activity of PI3K in the presence of p38 inhibition (Fig. 6C). Akt phosphorylation was not significantly altered in H/R but was enhanced in the presence of E2. PI3K inhibition with wortmannin reversed E2-mediated phosphorylation of Akt. Blocking p38 MAPK with SB203580, on the other hand, did not affect p-Akt stimulated by E2. This is consistent with the result from Fig. 6A, suggesting that PI3K/Akt lies proximal to p38 in the anti-apoptotic actions of E2. We then studied specifically the relationship between PI3K and p38beta as both were associated with E2-mediated suppression of ROS. Fig. 6D demonstrated that E2 stimulation of p38beta was mostly inhibited in the presence of wortmannin.

The data in total suggest that PI3K/Akt activated by E2 suppresses ROS and subsequently p38{alpha}. Activation of the proximal PI3K/Akt pathway by E2 led to increased p38beta activity. p38beta then suppressed ROS, with subsequent inhibition of pro-apoptotic p38{alpha} and apoptosis.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Understanding the pathophysiology of I/R injury and how endogenous molecules such as estrogen mitigate the resulting cardiomyocyte apoptosis is important. In the present study, we report novel mechanistic details of how estrogen protects cardiomyocytes from apoptosis. We found that E2 modulates two distinct and opposite functions of p38 isoforms in its protection of cardiomyocytes. In the H/R-induced apoptotic pathway, E2 inhibition of mitochondrial ROS is vital to cell survival, and protection by E2 is exerted through an integrated signaling network involving PI3K, ROS, p38{alpha}, and p38beta. By using specific inhibitors and dominant negative protein expression, we defined the order of the signaling cascade among these key molecules. E2-induced PI3K inhibited ROS, which is generated by I/R to activate p38{alpha} kinase. This is consistent with previous reports that redox intermediates mediate p38 MAPK activation in an angiotensin II-signaling system (40-42) and that exogenous addition of ROS stimulates activity of p38 (38, 43).

Of the four p38 MAPK family members, p38{alpha} is the predominant form in the cardiac tissue (26). We found in cultured cardiomyocytes that blocking this isoform with SB203580 resulted in almost complete reversal of apoptosis, attesting to the fact that p38{alpha} plays a major role in stress-induced apoptosis. Estrogen inhibited p38{alpha} via PI3K signaling to the suppression of ROS during simulated I/R. Part of the cellular insult is related to the mitochondrial ROS, which is a potent stimulator of apoptosis, especially in the setting of I/R (22). p38beta, on the other hand, is often pro-survival in function, thus acting opposite of p38{alpha} (29). Here, we showed that a dominant negative p38beta significantly reversed the survival effects of E2. Interestingly, hypoxic stress did not elicit a compensatory increase in p38beta activity. E2 acted to modulate the balance between the two isoforms favoring cell survival during stress.


Figure 5
View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 5.
Activity of p38beta in cardiomyocytes. A, the effect of E2 on the activity of p38beta. p38beta was immunoprecipitated from cardiomyocytes, and its phosphorylation of ATF2 was determined. Western blotting of immunoprecipitated total p38beta showed equal loading of proteins from each condition. *, p < 0.05 versus normoxia. +, p < 0.05 versus H/R. SB, SB203580. B, dominant negative p38beta (p38b DN) prevented E2-stimulated kinase activity. E2 no longer stimulated p38beta isolated from cells expressing a p38beta dominant negative mutant. Western blotting of immunoprecipitated total p38beta showed equal loading of proteins from each condition. Experiments were performed at normoxia. *, p < 0.05 versus normoxia. +, p < 0.05 versus E2. C, apoptosis in p38b DN-expressing cardiomyocytes. After infecting cells with p38b DN adenoviruses, cells were recovered, and H/R was applied in the presence or absence of E2. Annexin V-positive cells were counted. *, p < 0.01 versus normoxia. +, p < 0.01 versus H/R. ++, p < 0.05 versus H/R + E2. D, the effect of p38beta on ROS generation. After expression of p38b DN, H/R was applied, and intracellular ROS formation was assessed by detecting green fluorescent 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate in cells. Lanes not labeled with H/R represented experiments performed in normoxia. *, p < 0.01 versus normoxia. +, p < 0.05 versus H/R. ++, p < 0.05 versus H/R + E2.

 


Figure 6
View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 6.
Effect of PI3K activated by E2. A, PI3K inhibition of ROS formation. Cardiomyocytes underwent H/R in the presence or absence of a PI3K inhibitor, wortmannin (Wor), with or without E2. Cells positive for ROS were represented in percentage of total number of cells counted. *, p < 0.05 versus normoxia. +, p < 0.05 versus H/R. ++, p < 0.05 versus H/R + E2. B, the effect of PI3K inhibition on E2-mediated p38{alpha} suppression. ATF2 phosphorylated by p38{alpha} is assessed following H/R and in the presence or absence of E2 and/or wortmannin. Total p38{alpha} by Western blotting demonstrated equal loading of the kinase in each condition. C, Western blotting of phosphorylated Akt in the presence or absence of p38{alpha}/beta inhibitor, SB203580 (SB), or PI3K inhibitor, wortmannin. Western blotting of total Akt demonstrated equal amounts of the protein in each condition. D, p38beta kinase activity by ATF2 phosphorylation. Total p38beta by Western blotting was shown as control to demonstrate equal loading of the kinase in each condition. Concentrations used were E2 in 10 nM, wortmannin 100 nM, and SB203580 in 1 µM. Lanes not labeled with H/R represented experiments performed in normoxia.

 
We propose a working model of how estrogen protects cardiomyocytes from ischemia-reperfusion injury, pictured in Fig. 7. Upon hypoxic and oxidative insult, ROS is generated from mitochondria. The increased ROS stimulates activation of pro-apoptotic p38{alpha}, which exists in balance with the opposing p38beta until cellular stress occurs. However, in the presence of the E2-ER complex, anti-apoptotic signals are activated, probably at the cell membrane. This includes PI3K activation, subsequent inhibition of ROS generation, and suppression of p38{alpha} activity. E2-ER also augments pro-survival p38beta kinase. This activation is in part through PI3K/Akt activation stimulated by E2. p38beta and PI3K activation results in ROS suppression, removing a stimulus for p38{alpha} activation and apoptosis.


Figure 7
View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 7.
Illustration of anti-apoptotic actions of E2 in a cardiomyocyte.

 
One potential drawback of our model is that the results derive from neonatal myocytes. I/R injury is a pathological process most commonly associated with coronary artery disease, thus observed in adults. Although there are obviously differences between neonatal and adult cardiomyocytes, intracellular distribution and differential localization of ER isoforms upon E2 stimulation are identical between them.3 In addition, p38 MAPK is present and active both in neonatal and in adult cells (24). Thus, we believe that the findings from this study may be congruent to adult cardiomyocytes.

We used rotenone as an inhibitor of ROS generation because it has been effectively used to block ROS formation previously in various tissue types, including cardiomyocytes (35, 36, 44, 45). Myocardial I/R or hypoxia is associated with increased accumulation of succinate (46-48). Rotenone is believed to block ROS generated from the reverse flow of electrons in the presence of increased succinate during ischemia or hypoxia (49), in addition to interrupting further electron flow to complex III, another major site of ROS production in the heart (45, 50). Consistent with these published data, rotenone sufficiently suppressed ROS production in cardiomyocytes in our system (Fig. 4A).

Although respiratory chain inhibition may protect the heart from necrosis after an extensive ischemia, loss of cardiomyocytes specifically via apoptosis has been linked to hypoxia, I/R injury, and ROS production (14, 17, 18, 20-22, 51-53). Consistent with this, our simulated I/R system produced a negligible percentage of necrotic death (less than 5%). Thus, we believe that preserved viability by rotenone in this study was mainly due to suppression of ROS, thus reducing apoptotic death triggered by stress of H/R in vitro.

In conclusion, we report new findings in which E2 directly promotes cardiomyocyte survival upon simulated ischemia-reperfusion injury. Our findings may justify the assessment of estrogen compounds to enhance cardiomyocyte survival during ischemic stress in women.


   FOOTNOTES
 
* This work was supported by grants from the National Institutes of Health (to E. R. L.), American Heart Association (to J. K. K.), and the Department of Veterans Affairs (to E. R. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Div. of Endocrinology, Long Beach Veterans Affairs Medical Center, Medical Service (111-1), 5901 E. 7th St., Long Beach, CA 90822. Tel.: 562-826-5748; Fax: 562-826-5515; E-mail: ellis.levin{at}med.va.gov.

2 The abbreviations used are: E2, 17-beta-estradiol; H/R, hypoxia followed by reoxygenation; I/R, ischemia/reperfusion; ER, estrogen receptors; ROS, reactive oxygen species; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; PI, propidium iodide; NAC, N-acetyl-cysteine; DN, dominant negative. Back

3 J. K. Kim, A. Pedram, M. Razandi, and E. R. Levin, unpublished observation. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. The American Heart Association (1997) Biostatistical Fact Sheets, pp. 1-29, American Heart Association, Dallas, TX
  2. Maxwell, S. R. (1998) Basic Res. Cardiol. 93, Suppl. 2, 79-84[CrossRef][Medline] [Order article via Infotrieve]
  3. Godsland, I. F., Wynn, V., Crook, D., and Miller, N. E. (1987) Am. Heart J. 114, 1467-1503[CrossRef][Medline] [Order article via Infotrieve]
  4. Wren, B. G. (1992) Med. J. Aust. 157, 204-208[Medline] [Order article via Infotrieve]
  5. Grodstein, F., Stampfer, M. J., Colditz, G. A., Willett, W. C., Manson, J. E., Joffe, M., Rosner, B., Fuchs, C., Hankinson, S. E., Hunter, D. J., Hennekens, C. H., and Speizer, F. E. (1997) N. Engl. J. Med. 336, 1769-1775[Abstract/Free Full Text]
  6. Vaccarino, V., Krumholz, H. M., Berkman, L. F., and Horwitz, R. I. (1995) Circulation 91, 1861-1871[Abstract/Free Full Text]
  7. Hale, S. L., Birnbaum, Y., and Kloner, R. A. (1996) Am. Heart J. 132, 258-262[CrossRef][Medline] [Order article via Infotrieve]
  8. Zhai, P., Eurell, T. E., Cotthaus, R., Jeffery, E. H., Bahr, J. M., and Gross, D. R. (2000) Am. J. Physiol. 279, H2766-H2775
  9. Kanda, N., and Watanabe, S. (2003) J. Investig. Dermatol. 121, 1500-1509[CrossRef][Medline] [Order article via Infotrieve]
  10. Alexaki, V. I., Charalampopoulos, I., Kampa, M., Vassalou, H., Theodoropoulos, P., Stathopoulos, E. N., Hatzoglou, A., Gravanis, A., and Castanas, E. (2004) FASEB J. 18, 1594-1596[Abstract/Free Full Text]
  11. Razandi, M., Pedram, A., and Levin, E. R. (2000) J. Biol. Chem. 275, 38540-38546[Abstract/Free Full Text]
  12. Wang, Q., Li, X., Wang, L., Feng, Y. H., Zeng, R., and Gorodeski, G. (2004) Endocrinology 145, 5568-5579[Abstract/Free Full Text]
  13. Vilatoba, M., Eckstein, C., Bilbao, G., Frennete, L., Eckhoff, D. E., and Contreras, J. L. (2005) Transplant. Proc. 37, 399-403[CrossRef][Medline] [Order article via Infotrieve]
  14. Saraste, A., Pulkki, K., Kallajoki, M., Henriksen, K., Parvinen, M., and Voipio-Pulkki, L. M. (1997) Circulation 95, 320-323[Abstract/Free Full Text]
  15. Vanden Hoek, T. L., Li, C., Shao, Z., Schumacker, P. T., and Becker, L. B. (1997) J. Mol. Cell. Cardiol. 29, 2571-2583[CrossRef][Medline] [Order article via Infotrieve]
  16. Vanden Hoek, T. L., Qin, Y., Wojcik, K., Li, C. Q., Shao, Z. H., Anderson, T., Becker, L. B., and Hamann, K. J. (2003) Am. J. Physiol. 284, H141-H150
  17. Narula, J., Haider, N., Virmani, R., DiSalvo, T. G., Kolodgie, F. D., Hajjar, R. J., Schmidt, U., Semigran, M. J., Dec, G. W., and Khaw, B. A. (1996) N. Engl. J. Med. 335, 1182-1189[Abstract/Free Full Text]
  18. Patten, R. D., Pourati, I., Aronovitz, M. J., Baur, J., Celestin, F., Chen, X., Michael, A., Haq, S., Nuedling, S., Grohe, C., Force, T., Mendelsohn, M. E., and Karas, R. H. (2004) Circ. Res. 95, 692-699[Abstract/Free Full Text]
  19. Zhao, Z. Q., Nakamura, M., Wang, N. P., Wilcox, J. N., Shearer, S., Ronson, R. S., Guyton, R. A., and Vinten-Johansen, J. (2000) Cardiovasc. Res. 45, 651-660[Abstract/Free Full Text]
  20. Toyoda, Y., Shida, T., Wakita, N., Ozaki, N., Takahashi, R., and Okada, M. (1998) Cardiology 90, 149-151[CrossRef][Medline] [Order article via Infotrieve]
  21. Gottlieb, R. A., Burleson, K. O., Kloner, R. A., Babior, B. M., and Engler, R. L. (1994) J. Clin. Investig. 94, 1621-1628[Medline] [Order article via Infotrieve]
  22. Zhao, Z. Q. (2004) Curr. Opin. Pharmacol. 4, 159-165[CrossRef][Medline] [Order article via Infotrieve]
  23. See, F., Thomas, W., Way, K., Tzanidis, A., Kompa, A., Lewis, D., Itescu, S., and Krum, H. (2004) J. Am. Coll. Cardiol. 44, 1679-1689[Abstract/Free Full Text]
  24. Kaiser, R. A., Bueno, O. F., Lips, D. J., Doevendans, P. A., Jones, F., Kimball, T. F., and Molkentin, J. D. (2004) J. Biol. Chem. 279, 15524-15530[Abstract/Free Full Text]
  25. Jiang, Y., Chen, C., Li, Z., Guo, W., Gegner, J. A., Lin, S., and Han, J. (1996) J. Biol. Chem. 271, 17920-17926[Abstract/Free Full Text]
  26. Lemke, L. E., Bloem, L. J., Fouts, R., Esterman, M., Sandusky, G., and Vlahos, C. J. (2001) J. Mol. Cell. Cardiol. 33, 1527-1540[CrossRef][Medline] [Order article via Infotrieve]
  27. Saurin, A. T., Martin, J. L., Heads, R. J., Foley, C., Mockridge, J. W., Wright, M. J., Wang, Y., and Marber, M. S. (2000) FASEB J. 14, 2237-2246[Abstract/Free Full Text]
  28. Pedram, A., Razandi, M., Aitkenhead, M., and Levin, E. R. (2005) J. Biol. Chem. 280, 26339-26348[Abstract/Free Full Text]
  29. Wang, Y., Huang, S., Sah, V. P., Ross, J., Jr., Brown, J. H., Han, J., and Chien, K. R. (1998) J. Biol. Chem. 273, 2161-2168[Abstract/Free Full Text]
  30. Vitale, M., Zamai, L., Mazzotti, G., Cataldi, A., and Falcieri, E. (1993) Histochemistry 100, 223-229[CrossRef][Medline] [Order article via Infotrieve]
  31. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. R., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Liri, G. P., White, J. R., Adams, J. L., and Young, P. R. (1994) Nature 372, 739-746[CrossRef][Medline] [Order article via Infotrieve]
  32. Pugazhenthi, S., Miller, E., Sable, C., Young, P., Heidenreich, K. A., Boxer, L. M., and Reusch, J. E. (1999) J. Biol. Chem. 274, 27529-27535[Abstract/Free Full Text]
  33. Martin, J. L., Avkiran, M., Quinlan, R. A., Cohen, P., and Marber, M. S. (2001) Circ. Res. 89, 750-752[Abstract/Free Full Text]
  34. Gill, C., Mestril, R., and Samali, A. (2002) FASEB J. 16, 135-146[Abstract/Free Full Text]
  35. Chen, Q., Vazquez, E. J., Moghaddas, S., Hoppel, C. L., and Lesnefsky, E. J. (2003) J. Biol. Chem. 278, 36027-36031[Abstract/Free Full Text]
  36. Becker, L. B., vanden Hoek, T. L., Shao, Z. H., Li, C. Q., and Schumacker, P. T. (1999) Am. J. Physiol. 277, H2240-2246[Medline] [Order article via Infotrieve]
  37. Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K., Ledgerwood, E. C., Smith, R. A., and Murphy, M. P. (2001) J. Biol. Chem. 276, 4588-4596[Abstract/Free Full Text]
  38. Kulisz, A., Chen, N., Chandel, N. S., Shao, Z., and Schumacker, P. T. (2002) Am. J. Physiol. 282, L1324-L1329
  39. Marushige, K., and Marushige, Y. (1999) Anticancer Res. 19, 3865-3871[Medline] [Order article via Infotrieve]
  40. Wenzel, S., Taimor, G., Piper, H. M., and Schluter, K. D. (2001) FASEB J. 15, 2291-2293[Free Full Text]
  41. Palomeque, J., Sapia, L., Hajjar, R. J., Mattiazzi, A., and Vila Petroff, M. G. (2006) Am. J. Physiol. 290, H96-H106
  42. Nishida, M., Tanabe, S., Maruyama, Y., Mangmool, S., Urayama, K., Nagamatsu, Y., Takagahara, S., Turner, J. H., Kozasa, T., Kobayashi, H., Sato, Y., Kawanishi, T., Inoue, R., Nagao, T., and Kurose, H. (2005) J. Biol. Chem. 280, 18434-18441[Abstract/Free Full Text]
  43. Cicconi, S., Ventura, N., Pastore, D., Bonini, P., Di Nardo, P., Lauro, R., and Marlier, L. N. (2003) J. Cell Physiol. 195, 27-37[CrossRef][Medline] [Order article via Infotrieve]
  44. Ichikawa, H., Takagi, T., Uchiyama, K., Higashihara, H., Katada, K., Isozaki, Y., Naito, Y., Yoshida, N., and Yoshikawa, T. (2004) Redox Rep. 9, 313-316[CrossRef][Medline] [Order article via Infotrieve]
  45. Lesnefsky, E. J., Chen, Q., Moghaddas, S., Hassan, M. O., Tandler, B., and Hoppel, C. L. (2004) J. Biol. Chem. 279, 47961-47967[Abstract/Free Full Text]
  46. Wiesner, R. J., Deussen, A., Borst, M., Schrader, J., and Grieshaber, M. K. (1989) J. Mol. Cell. Cardiol. 21, 49-59[Medline] [Order article via Infotrieve]
  47. Kato, K., Matsubara, T., and Sakamoto, N. (1994) Nagoya J. Med. Sci. 57, 43-50[Medline] [Order article via Infotrieve]
  48. Hohl, C., Oestreich, R., Rosen, P., Wiesner, R., and Grieshaber, M. (1987) Arch. Biochem. Biophys. 259, 527-535[CrossRef][Medline] [Order article via Infotrieve]
  49. Gyulkhandanyan, A. V., and Pennefather, P. S. (2004) J. Neurochem. 90, 405-421[CrossRef][Medline] [Order article via Infotrieve]
  50. Turrens, J. F., and Boveris, A. (1980) Biochem. J. 191, 421-427[Medline] [Order article via Infotrieve]
  51. Tanaka, M., Ito, H., Adachi, S., Akimoto, H., Nishikawa, T., Kasajima, T., Marumo, F., and Hiroe, M. (1994) Circ. Res. 75, 426-433[Abstract/Free Full Text]
  52. Fliss, H., and Gattinger, D. (1996) Circ. Res. 79, 949-956[Abstract/Free Full Text]
  53. Sharov, V. G., Todor, A., Suzuki, G., Morita, H., Tanhehco, E. J., and Sabbah, H. N. (2003) Eur. J. Heart Fail. 5, 121-129[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
A. Pedram, M. Razandi, D. Lubahn, J. Liu, M. Vannan, and E. R. Levin
Estrogen Inhibits Cardiac Hypertrophy: Role of Estrogen Receptor-{beta} to Inhibit Calcineurin
Endocrinology, July 1, 2008; 149(7): 3361 - 3369.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
R. Raju and I. H. Chaudry
Sex Steroids/Receptor Antagonist: Their Use as Adjuncts After Trauma-Hemorrhage for Improving Immune/Cardiovascular Responses and for Decreasing Mortality from Subsequent Sepsis
Anesth. Analg., July 1, 2008; 107(1): 159 - 166.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. J. Merkel, L. Liu, Z. Cao, W. Packwood, P. D. Hurn, and D. M. Van Winkle
Estradiol abolishes reduction in cell death by the opioid agonist Met5-enkephalin after oxygen glucose deprivation in isolated cardiomyocytes from both sexes
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H409 - H415.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
H. L Jeanes, C. Tabor, D. Black, A. Ederveen, and G. A Gray
Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER){alpha} agonist and unaffected by an ER{beta} antagonist
J. Endocrinol., June 1, 2008; 197(3): 493 - 501.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
V. M. Miller and S. P. Duckles
Vascular Actions of Estrogens: Functional Implications
Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W.-H. Kan, J.-T. Hsu, Z.-F. Ba, M. G. Schwacha, J. Chen, M. A. Choudhry, K. I. Bland, and I. H. Chaudry
p38 MAPK-dependent eNOS upregulation is critical for 17{beta}-estradiol-mediated cardioprotection following trauma-hemorrhage
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2627 - H2636.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
Y. Yin, W.-W. Huang, C. Lin, H. Chen, A. MacKenzie, and L. Ma
Estrogen Suppresses Uterine Epithelial Apoptosis by Inducing Birc1 Expression
Mol. Endocrinol., January 1, 2008; 22(1): 113 - 125.
[Abstract] [Full Text] [PDF]